Figure 4
The tumor-inhibitory effect of chemerin is partly reserved in Rag1−/− mice. (a, b) Ctrl-Hepa1-6 and chemerin-Hepa1-6 cells were injected subcutaneously into male C57BL/6 WT and Rag1−/− mice (a), and some WT mice were randomized to be intraperitoneally injected with anti-CD8 neutralizing antibody (200 μg/mouse) every 3 days from 3 days before inoculation of tumor cells until mice were killed (b). Tumor growth was measured at the indicated time points. (c) Numbers of Gr-1+ and F4/80+ cells counted in tumor sections following IHC staining. (d) Left, representative photomicrographs of IHC staining of CD31 in tumor sections. Right, microvessel density (MVD) was calculated by surface quantification of CD31-positive cells. Statistical significance calculated by analysis of variance (ANOVA). Original magnification, × 200; scale bar, 50 μm. (e) Quantitative reverse transcriptase (qRT)–PCR analysis of the expression of proangiogenic genes in tumor tissues from Rag1−/− mice that received Ctrl-Hepa1-6 and chemerin-Hepa1-6 cells. Columns and error bars represent mean±s.e.m. (n=6 per group). *P<0.05, **P<0.01, ***P<0.001. Similar results were obtained from two independent experiments.
